Antidepressant Use in Fathers and Child Outcomes

Overview of Antidepressant Research

The impact of antidepressant use in women during pregnancy on child outcomes has been extensively researched. However, the effects of a father’s antidepressant use during the conception period—specifically concerning birth defects and negative health outcomes in children—remain less explored. As antidepressant prescriptions continue to rise, understanding this aspect is increasingly important.

Effects of Antidepressants on Sperm

Laboratory studies indicate that antidepressants may adversely affect sperm health. These effects can include sperm destruction, reduced concentration and motility, alterations to sperm structure, and increased DNA damage. Despite a limited number of studies focusing on the impact of antidepressants on sperm, there is growing interest in the birth outcomes for children conceived by fathers exposed to these medications.

Research Study on Paternal Antidepressant Use

Researchers in Sweden conducted an observational prospective cohort study to explore the relationship between paternal antidepressant use at conception and various birth outcomes, including preterm birth, birth defects, autism, and intellectual disability. The study analyzed data from a Swedish national group study database, which included 170,508 eligible children. Researchers categorized fathers into three groups based on their antidepressant exposure:

1. Fathers exposed to antidepressants during the conception period (defined as four weeks before and four weeks after conception).
2. Fathers who began antidepressant treatment during the pregnancy only.
3. Fathers with no antidepressant exposure during the conception period.

To ensure the accuracy of their findings, researchers adjusted for several factors, including the parents’ ages at conception, mental health history, the mother’s antidepressant use, and socioeconomic status.

Findings on Antidepressant Use During Conception

The study found no significant association between a father’s antidepressant use during the conception period and adverse birth outcomes when comparing fathers with and without exposure during this time. Additionally, there were no notable differences observed when comparing paternal antidepressant exposure starting after conception and during pregnancy. Interestingly, the analysis revealed that exposure to antidepressants during conception correlated with a decreased risk of intellectual disability, while exposure after conception was associated with an increased risk. Researchers suggest that underlying mental illness in fathers may contribute to the risk of intellectual disability in their children rather than the antidepressant use itself.

Implications and Need for Further Research

The findings align with previous studies regarding the prevalence of birth outcomes such as autism and intellectual disability. Given the study’s large population size and comprehensive data, the results hold relevance for a broader audience. However, researchers caution that these findings are specific to the Swedish population and may not be universally applicable due to variations in genetic factors and cultural influences.

The study concludes that paternal antidepressant use during the conception period does not appear to be causally linked to an increased risk of birth defects or adverse birth outcomes. This information may assist in making informed antidepressant treatment decisions during family planning for prospective fathers. Nonetheless, due to the limited data available, the researchers emphasize the critical need for additional studies to validate these findings.

Reference

Viktorin, A., Levine, S. Z., Altemus, M., Reichenberg, A., & Sandin, S. (2018). Paternal use of antidepressants and offspring outcomes in Sweden: Nationwide prospective cohort study. BMJ. doi:10.1136/bmj.k2233